PATHOPHYSIOLOGICAL INSIGHTS INTO FACIAL HYPERPIGMENTATION AND AESTHETIC TREATMENT MODALITIES DOI Creative Commons
Yuliya Fedorchenko

Anti-Aging Eastern Europe, Journal Year: 2025, Volume and Issue: 4(1), P. 14 - 19

Published: April 2, 2025

Facial hyperpigmentation, including melasma and post-inflammatory poses a significant dermatological psychosocial challenge. These conditions arise from complex interplay of genetic factors, hormonal influences, environmental exposures (UV, VL, IR), with management particularly challenging in skin color. This narrative review synthesizes current insights into the pathophysiology hyperpigmentation—emphasizing roles MC1R, tyrosinase, related enzymes melanogenesis—and evaluates both established emerging treatment modalities. A systematic literature search up to February 2025 identified studies addressing topical, oral, laser, combination therapies. Topical treatments, such as 5% alpha-arbutin 2% kojic acid cream, demonstrated efficacy comparable triple formulations but lower recurrence (p = 0.004). Low-dose tranexamic acid, delivered orally or via mesotherapy, significantly reduced modified Melasma Area Severity Index (mMASI) scores 0.02) improved quality life 0.03). Laser therapies—including picosecond Nd:YAG 755-nm lasers—produced mMASI reductions < 0.001), nonablative 1,927-nm fractional laser achieving 43% improvement pigmentation among darker types 0.0001). Adjunctive procedures, glycolic peels, supramolecular salicylic niacinamide, microneedling, further enhanced clinical outcomes 0.05–p 0.001). Preliminary evidence also supports acupuncture promising complementary approach. In summary, an individualized, multimodal strategy is essential for optimal facial hyperpigmentation. Further controlled are warranted refine these protocols enhance long-term therapeutic efficacy.

Language: Английский

PATHOPHYSIOLOGICAL INSIGHTS INTO FACIAL HYPERPIGMENTATION AND AESTHETIC TREATMENT MODALITIES DOI Creative Commons
Yuliya Fedorchenko

Anti-Aging Eastern Europe, Journal Year: 2025, Volume and Issue: 4(1), P. 14 - 19

Published: April 2, 2025

Facial hyperpigmentation, including melasma and post-inflammatory poses a significant dermatological psychosocial challenge. These conditions arise from complex interplay of genetic factors, hormonal influences, environmental exposures (UV, VL, IR), with management particularly challenging in skin color. This narrative review synthesizes current insights into the pathophysiology hyperpigmentation—emphasizing roles MC1R, tyrosinase, related enzymes melanogenesis—and evaluates both established emerging treatment modalities. A systematic literature search up to February 2025 identified studies addressing topical, oral, laser, combination therapies. Topical treatments, such as 5% alpha-arbutin 2% kojic acid cream, demonstrated efficacy comparable triple formulations but lower recurrence (p = 0.004). Low-dose tranexamic acid, delivered orally or via mesotherapy, significantly reduced modified Melasma Area Severity Index (mMASI) scores 0.02) improved quality life 0.03). Laser therapies—including picosecond Nd:YAG 755-nm lasers—produced mMASI reductions < 0.001), nonablative 1,927-nm fractional laser achieving 43% improvement pigmentation among darker types 0.0001). Adjunctive procedures, glycolic peels, supramolecular salicylic niacinamide, microneedling, further enhanced clinical outcomes 0.05–p 0.001). Preliminary evidence also supports acupuncture promising complementary approach. In summary, an individualized, multimodal strategy is essential for optimal facial hyperpigmentation. Further controlled are warranted refine these protocols enhance long-term therapeutic efficacy.

Language: Английский

Citations

0